In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung Diseases-Reference-Cited by-同舟云学术

In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung Diseases

Published:2009-06-03 Issue:3 Volume:11 Page:414-423
ISSN:1550-7416
Container-title:The AAPS Journal
language:en
Short-container-title:AAPS J

Author:

Lee Sau Lawrence,Adams Wallace P.,Li Bing V.,Conner Dale P.,Chowdhury Badrul A.,Yu Lawrence X.

Publisher

Springer Science and Business Media LLC

Subject

Pharmaceutical Science

Link

http://link.springer.com/content/pdf/10.1208/s12248-009-9121-4.pdf

Reference35 articles.

1. Weibel ER. Morphometry of the human lung. Berlin: Springer; 1963.

2. Hickey AJ, Thompson DC. Physiology of the airways. In: Hickey AJ, editor. Pharmaceutical inhalation aerosol technology. 2nd ed. New York: Marcel Dekker; 2004. p. 1–29.

3. Carstairs JR, Nimmo AJ, Barnes PJ. Autoradiographic visualization of beta-adrenoceptor subtypes in human lung. Am Rev Respir Dis. 1985;132:541–7.

4. Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of β2-agonist particle size. Am J Respir Crit Care Med. 2005;172:1497–504.

5. Mak JC, Barnes PJ. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am Rev Respir Dis. 1990;141:1559–68.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quality by Design in Pulmonary Drug Delivery: A Review on Dry Powder Inhaler Development, Nanotherapy Approaches, and Regulatory Considerations;AAPS PharmSciTech;2024-08-02

2. Performance Testing for Dry Powder Inhaler Products: Towards Clinical Relevance;KONA Powder and Particle Journal;2023-01-10

3. Mechanistic modeling of generic orally inhaled drug products: A workshop summary report;CPT: Pharmacometrics & Systems Pharmacology;2022-12-20

4. Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development;Pharmaceutics;2022-11-17

5. Scientific and regulatory activities initiated by the U.S. Food and drug administration to foster approvals of generic dry powder inhalers: Bioequivalence perspective;Advanced Drug Delivery Reviews;2022-11